Clinical trial failures

Disease area hub

Hematology (non-onc) clinical trial failures

Review 336 stopped hematology (non-onc) clinical trials, including failure signals, sponsors, phases, and stop reasons from ClinicalTrials.gov records.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 30 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials336
Likely biological signals30
Shown below100

Dominant stop reasons

OPERATIONAL
178
OTHER/UNKNOWN
128
SAFETY
19
EFFICACY/FUTILITY
11

Notable sponsors

Pfizer
10
Hoffmann-La Roche
8
Novartis Pharmaceuticals
8
Baylor College of Medicine
7
Fred Hutchinson Cancer Center
6

Related phases

Phase II
116
Phase I
86
Phase III
66
Phase IV
36
Unknown
27

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04188509: Open-Label Extension of Voxelotor

Phase III Sickle Cell Disease trial by Pfizer. Stop reason: SAFETY.

Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment.

NCT04474314: A Study of IMR-687 in Subjects With Sickle Cell Disease

Phase II Sickle Cell Disease trial by Cardurion Pharmaceuticals, Inc.. Stop reason: EFFICACY/FUTILITY.

A recently conducted Interim analysis of IMR-SCD-301 demonstrated that while IMR-687 was generally well-tolerated, it failed to meet its primary efficacy endpoint. So, the sponsor has decided to discontinue this study.

NCT04411082: A Study of IMR-687 in Subjects With Beta Thalassemia

Phase II β Thalassemia trial by Cardurion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.

IMR-BTL-201demonstrated that while IMR-687 was generally well-tolerated, it failed to show any meaningful benefit in transfusion burden or improvement in most disease-related biomarkers. So, the sponsor has decided to discontinue this study

NCT02863068: Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers

Phase II Sickle Cell Disease trial by caterina P minniti. Stop reason: OPERATIONAL.

Study terminated prior to achieving target enrollment due to slow recruitment and high cost of obtaining new study drug. Since no additional funds were to be available due to end of the funding period, remaining funds were expended on analyses.

NCT04420585: Desmopressin for Bedwetting in Children With SCD

Phase IV Nocturnal Enuresis trial by Montefiore Medical Center. Stop reason: OPERATIONAL.

Study was not able to meet recruitment after 9 years of trying to enroll patients on different versions of the protocol and changing recruitment strategies.

NCT02373241: Preventing Sickle Cell Kidney Disease

Phase II Anemia, Sickle Cell trial by University of Alabama at Birmingham. Stop reason: OTHER/UNKNOWN.

Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.

NCT00540995: Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Phase I Adult Acute Myeloid Leukemia in Remission trial by City of Hope Medical Center. Stop reason: SAFETY.

Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than FTBI. Likely due to the giving of Busulfan prior to radiation delivery. Therefore, the study was abandoned and no further patients were accrued.

NCT05927012: A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

Phase II Iron Deficiency Anemia trial by Keros Therapeutics, Inc.. Stop reason: OPERATIONAL.

Despite several attempts to recruit eligible participants and major protocol amendments to increase the recruitment rate, recruitment challenges remained. Therefore, the Sponsor has made the decision to terminate the KER047-IR-202 Study globally.